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Bronchopulmonary dysplasia (BPD) can evolve in prematurely
born infants who require mechanical ventilation because of hyaline
membrane disease (HMD). The development of BPD can be di-
vided in an acute, a regenerative, a transitional, and a chronic phase.
During these different phases, extensive remodeling of the lung
parenchyma with re-epithelialization of the alveoli and formation of
fibrosis occurs. Matrix metalloproteinase-1 (MMP-1) is an enzyme
that is involved in re-epithelialization processes, and dysregulation
of MMP-1 activity contributes to fibrosis. Localization of MMP-1
and its inhibitors, tissue inhibitor of metalloproteinase (TIMP)-1 and
TIMP-2, were investigated in lung tissue obtained from infants who
died during different phases of BPD development. In all studied
cases (n  50) type-II pneumocytes were found to be immunore-
active for MMP-1, TIMP-1, and TIMP-2. During the acute and
regenerative phase of BPD, type-II pneumocytes re-epithelialize the
injured alveoli. This may suggest that MMP-1 and its inhibitors,
expressed by type-II pneumocytes, play a role in the re-
epithelialization process after acute lung injury. Although MMP-1
staining intensity remained constant in type-II pneumocytes during
BPD development, TIMP-1 increased during the chronic fibrotic
phase. This relative elevation of TIMP-1 compared with MMP-1 is
indicative for reduced collagenolytic activity by type-II pneumo-
cytes in chronic BPD and may contribute to fibrosis. Fibrotic foci in
chronic BPD contained fibroblasts immunoreactive for MMP-1 and
TIMP-1 and -2. This may indicate that decreased collagen turnover
by fibroblasts contributes to fibrosis in BPD development. (Pediatr
Res 50: 761–766, 2001)
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Respiratory distress syndrome develops within minutes after
birth in premature infants and is associated with surfactant
deficiency of the immature lung (1, 2). Pathologically, it is
called hyaline membrane disease (HMD), with the formation
of hyaline membranes in the terminal airways being one of the
most striking pathologic features (3).
Hyaline membrane formation is caused by necrosis and
desquamation of epithelial cells lining the alveolar basement
membrane and the occurrence of pulmonary edema (3–5). To
sustain life, infants are treated with mechanical ventilation and
supplemental oxygen, which are both risk factors for the
progression of HMD toward bronchopulmonary dysplasia
(BPD) (6).
BPD, also called chronic lung disease of prematurity, can be
regarded as the end stage of HMD treatment and is associated
with mortality and long term pulmonary morbidity (6, 7). The
development from HMD to BPD is characterized by extensive
tissue remodeling and can be divided into four phases based on
days after birth: acute (2–4 d), regenerative (4–8 d), transi-
tional (8–16 d), and chronic (16 d) (8). A main feature of the
acute and regenerative phase is re-epithelialization of the de-
nuded alveoli. The transitional and chronic phases are charac-
terized by alveoli primarily lined with type-II pneumocytes and
the occurrence of fibrotic areas and increased numbers of
fibroblasts (3, 9, 10).
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During the re-epithelialization process, hyaline membranes
form a matrix on which type-II pneumocytes adhere and
regenerate. This process incorporates hyaline membranes into
the alveolar septal wall. Incorporated hyaline membranes,
which contain fibronectin, are associated with areas of fibrosis
during BPD development (9, 11, 12).
Matrix metalloproteinases (MMPs) are a group of enzymes
capable of degrading extracellular matrix proteins. MMPs play
a critical role in normal physiologic processes like develop-
ment, tissue remodeling, inflammation, angiogenesis, wound
healing, and cell migration (13). The expression of MMPs is
regulated at the transcriptional level by cytokines, growth
factors, and extracellular matrix components (14, 15, 16).
MMPs are secreted as latent pro-enzymes and require proteo-
lytic cleavage for activation. MMP-1 is capable of degrading
the fibrillar collagens—type-I, -II, -III, collagen type-X, gela-
tin, and proteoglycans (17).
In vitro studies have shown that type-II pneumocytes, the
cells that initiate alveolar re-epithelialization, are able to pro-
duce MMP-1 and thereby promote their own migration (18,
19). Therefore, MMP-1 may play a role in the re-epithelializa-
tion process of the alveoli during the acute and regenerative
phase of BPD development, comparable with the role for
MMP-1 in re-epithelialization of the skin after injury (20, 21).
Tissue inhibitors of matrix metalloproteinase (TIMP)-1 and
TIMP-2 inhibit active MMP-1(22). It was shown that disturbed
MMP-1, TIMP-1, and TIMP-2 regulation plays an important
role in pathologic processes like fibrotic liver disease and
pulmonary fibrosis (23–27).
Therefore, we expect MMP-1, TIMP-1, and TIMP-2 to
contribute to the remodeling process of lung tissue when HMD
progresses toward BPD. This urged us to study the immuno-
histochemical localization of MMP-1, TIMP-1, and TIMP-2 in
lung tissue obtained from infants who died during different
phases of BPD development.
METHODS
Patients. Autopsy lung specimens were selected in the files
of the department of Pathology from the years 1988–1998,
based on premature infants who where histologically and
clinically diagnosed as HMD/BPD. HMD was clinically de-
fined as respiratory distress for which ventilation was neces-
sary and a pulmonary x-ray pattern compatible with HMD
(28). All patients were still on oxygen when they died. There-
fore, per definition all patients that died after 28 d fulfilled the
clinical BPD definition according to Bancalari (29). Staging of
the histologic samples was performed according to Rosan (8).
In total, 50 prematurely born infants with pathologic findings
of BPD or HMD, who died of respiratory insufficiency, were
selected (all patients (n  12) before 1990 died because of
respiratory insufficiency alone; after 1990, 26 infants died
because of respiratory insufficiency alone; in the other 12
patients respiratory insufficiency coexisted with heart failure or
intraventricular hemorrhage). As controls, specimens were
taken from three term infants who died of nonpulmonary
causes and lived for 9,14, and 30 d, respectively.
Immunohistochemistry. Paraffin embedded lung tissue was
cut into four m sections, incubated overnight at 37°C, depar-
affinized, and rehydrated. Afterward, the slides were washed in
phosphate-buffered saline (PBS, pH 7.8) for 5 min and incu-
bated with 0.1% pepsin A (Sigma Chemical Co. Chemical
Company, St. Louis, MO, U.S.A.) in 0.01M HCl for 30 min at
37°C for antigen retrieval. The slides were subsequently rinsed
in PBS of 4°C for 5 min, followed by blocking of endogenous
biotin activity with an avidin/biotin blocking kit (Vector Lab-
oratories, Burlingame, CA, U.S.A.). Afterward, the slides were
rinsed for 15 min in PBS followed by 10 min in PBS contain-
ing 0.2% Tween 20. The slides were then incubated for 5 min
with PBS containing 1% bovine serum albumin (BSA) fol-
lowed by a 1 h incubation with PBS containing 1% BSA and
10% normal human serum (NHS). This was followed by
rinsing the slides for two times 5 min in washbuffer (PBS
containing 0.1% BSA and 0.2% Tween 20). Subsequently, the
slides were incubated for 1 h with 10% normal goat serum
diluted in PBS containing 1% BSA for MMP-1 and TIMP-2
staining or 10% normal rabbit serum diluted in PBS containing
1% BSA for TIMP-1 staining. Then the slides were incubated
with the primary antibodies diluted in PBS containing 1% BSA
and 10% normal goat or rabbit serum (mouse anti-human
MMP-1; 1:200 dilution; mouse anti-human TIMP-2; 1:20 di-
lution, ICN Biomedicals, Aurora, OH, and goat anti-human
TIMP-1; 1:40 dilution, Santa Cruz Biotechnology, Santa Cruz,
CA, U.S.A.) overnight at 4°C. Afterward, the slides were
rinsed for 5 min in washbuffer, which was followed by two
wash steps of 15 min. Subsequently, the slides were incubated
for 30 min with biotin-labeled goat-anti-mouse (Biogenex, San
Ramon, CA, U.S.A.) or rabbit-anti-goat (DAKO, Glostrup,
Denmark) at a 1:50 and 1:20 dilution in PBS containing 1%
BSA and 10% NHS, respectively. Then the slides were rinsed
for 5 min followed by two times 15 min in washbuffer. This
was followed by incubating the slides for 30 min with a 1:50
dilution of Streptavidin-alkaline-phosphatase (Biogenex) in
PBS containing 1% BSA. Afterward, the slides were rinsed
once 5 and once 15 min with washbuffer and rinsed for 5 min
in 0.2M Tris-HCl (pH 8.0). Subsequently, the slides were
incubated for 30 min with New Fuchsin substrate (Chroma,
Stuttgart, Germany). Finally the slides were rinsed with PBS,
counterstained with Mayers hematoxylin (Merck, Darmstadt,
Germany) and mounted in Kaiser’s glycerol (Merck). Control
staining was performed by substitution of the primary antibody
with PBS. R.R.d.K. and L.B. performed the evaluation of the
stained sections in a blinded fashion. The cells and structures
examined in this study were the alveolar macrophage, the
alveolar type-II pneumocyte, the alveolar basement membrane,
and fibroblasts in fibrotic foci. The staining intensity of the
sections was scored in a semiquantitative manner according to
the following method: no staining  0, diffuse very faint
staining  1, diffuse faint staining  2, diffuse moderate
staining  3, and diffuse strong staining  4.
Statistical analysis. Data on staining intensity are presented
as median and percentiles (10% to 90%) for the different
phases of BPD development. For evaluation of differences in
staining intensity between different phases of BPD develop-
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ment the Mann-Whitney U test was used. A p value less than
0.05 was considered significant.
RESULTS
Patients. BPD is considered as a gradually developing se-
quel of the original diagnosed HMD (acute phase of BPD
development) and its treatment (8). Therefore, we applied the
time phases for BPD development, according to Rosan, to the
patient group (8). Twenty seven patients were included in the
acute phase (0–4 d), seven in the regenerative phase (5–8 d),
nine in the transitional phase (9–16 d), and seven in the chronic
phase (16 d). The control patients were regarded as one
group, independent of their age at death. Clinical data of the
different phases of BPD development and of control patients
are shown in Table 1.
MMP-1, TIMP-1, and TIMP-2 expression. An overview of
the immunohistochemical detection for MMP-1, TIMP-1, and
TIMP-2, presented as positive or negative immunoreactivity, is
shown in Table 2.
Control lung tissue. Control lung tissue revealed scattered
MMP-1, TIMP-1, and -2 positive type-II pneumocytes and
alveolar macrophages. TIMP-1 reactivity was also detected in
the alveolar basement membrane (Fig. 1).
Acute phase (0-4 d). Lung tissue of the patients who died
early in the acute phase (1 d) was characterized by extensive
loss of alveolar epithelial cells and the formation of hyaline
membranes. Because of extensive loss of alveolar epithelial
cells, virtually no reactivity with MMP-1, TIMP-1, and
TIMP-2 was observed in the alveolar epithelium. However, if
cuboidal type-II-like pneumocytes were present, they stained
positive for MMP-1, TIMP-1, and TIMP-2. During progression
toward day 4 in the acute phase, the lung tissue showed hyaline
membranes covering cells positive for MMP-1, TIMP-1, and
TIMP-2. Furthermore, regenerating epithelial cells positive for
MMP-1, TIMP-1, and TIMP-2 epithelialized the hyaline mem-
branes, incorporating them into the alveolar septum. In most
cases a clear positive staining for TIMP-1 was localized to the
alveolar basement membrane, which was observed underneath
epithelial cells as well as underneath hyaline membranes.
Alveolar macrophages showed no difference in immunostain-
ing for MMP-1, TIMP-1, and TIMP-2 compared with control
lung tissue.
Regenerative phase (5–8 d). During the regenerative phase
hyaline membranes were still present in the tissue and clearly
became incorporated into the alveolar wall. The incorporated
membranes were covered by cuboidal type-II-like pneumo-
cytes that stained positive for MMP-1, TIMP-1, and TIMP-2
(Fig. 2). In most cases TIMP-1 positivity was also observed in
parts of the alveolar basement membrane, similar to the situ-
ation in the acute phase. Alveolar macrophages present in this
phase showed a similar positivity for MMP-1, TIMP-1, and
TIMP-2 as detected in the control lung tissue.
Transitional phase (9–16 d). During the transitional phase
less hyaline membranes were present. If present, they were
covered with cuboidal type-II-like pneumocytes, which stained
positive for MMP-1, TIMP-1, and TIMP-2. Furthermore, the
alveolar surface appeared to be covered exclusively with type-
II-like pneumocytes, which were MMP-1, TIMP-1, and
TIMP-2 positive. Alveolar macrophages, which were more
frequently present than in the previous stages, also stained
positive for MMP-1, TIMP-1, and TIMP-2 (Fig. 3). TIMP-1
immunoreactivity in the alveolar basement membrane differed
from barely detectable in some patients to prominent in others.
Chronic phase (>16 d). During the chronic phase hyaline
membranes were virtually absent. The alveoli appeared to be
covered exclusively with type-II-like pneumocytes immunore-
active for MMP-1, TIMP-1, and TIMP-2. In some cases the
alveoli appeared emphysematous. Alveolar macrophages also
revealed positive staining for MMP-1, TIMP-1, and TIMP-2.
During this chronic phase, interstitial fibrosis was a prominent
feature. Fibrotic areas contained fibroblasts positive for
MMP-1, TIMP-1, and TIMP-2 (Fig. 4). Immunostaining for
TIMP-1 in the alveolar basement membrane varied from barely
detectable in some patients to prominent in others. If the
primary antibody was omitted, no immunoreactivity was de-
tected (Fig. 4D).
Semiquantitative analysis of immunoreactivity during
BPD development. Semiquantitative analysis of immunoreac-
tivity revealed no difference in MMP-1 and TIMP-2 staining
intensity between the four phases of BPD development. How-
ever, TIMP-1 showed a marked increase in staining intensity in
the type-II pneumocytes that formed the alveolar lining in the
chronic phase of BPD compared with the earlier phases (Fig.
5).
DISCUSSION
In the present study we investigated the expression pattern of
MMP-1 and its inhibitors, TIMP-1 and TIMP-2, in the lung
during the development of BPD. MMP-1 was co-localized with
TIMP-1 and TIMP-2 in type-II pneumocytes and alveolar
macrophages. TIMP-1 also localized to the alveolar basement
membrane.
The expression of MMP-1, TIMP-1, and TIMP-2 by type-II
pneumocytes and alveolar macrophages in the healthy lung
Table 1. Clinical data of BPD and control patients
BPD stage
Gestational age
(weeks)*
Age at death
(days)*
Weight at death
(kilograms)* Male:Female
Number of
patients
Acute phase 28.9 (24.9–36) 2 (0.08–4) 1.1 (0.58–3.0) 2:1 27
Regenerative phase 25.6 (25–30) 6 (5–8) 1.1 (0.56–1.4) 4:3 7
Transitional phase 27.9 (26.3–30) 13 (9–16) 1.1 (0.77–1.7) 7:2 9
Chronic phase 28 (25–31.7) 35 (21–304) 1.1 (0.85–5.0) 6:1 7
Controls term 14 (9–30) 2.9 (2.9–3.7) 1:2 3
* Median value (range).
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may play a role in the extracellular matrix turnover, which is a
constant feature in lung tissue (30, 31). The presence of
TIMP-1 in the basement membrane may prevent this structure
from degradation by MMPs or may provide a barrier function
for active MMPs to reach the lung interstitium to control
extracellular matrix turnover.
After lung injury and during lung development, the type-II
pneumocyte is the progenitor cell for the formation of a
functional alveolar epithelium (32, 33). Migration of type-II
pneumocytes over hyaline membrane-like matrices has been
suggested to play an important role during re-epithelialization
after acute injury. The 21-integrin on type-II pneumocytes
mediates the migration on collagen type-I, a substrate for and
inducer of MMP-1 production (17, 34, 35). Recently, an in
vitro study described that MMP-1 decreased the type-II pneu-
mocyte cytoskeleton stiffness, the adhesion to collagen type-I,
and increased cell migration across collagen type-I (19). Re-
garding these observations and the expression of MMP-1,
TIMP-1, and TIMP-2 by type-II pneumocytes on hyaline
membranes in the acute and regenerative phases of BPD
development, we speculate that MMP-1 is involved in re-
epithelialization of the alveolar surface during the acute and
regenerative phase of BPD development. The colocalization of
TIMP-1 and TIMP-2 with MMP-1 indicates that these inhibi-
tors regulate the activity of MMP-1 during this process. Anal-
ysis of lung homogenates could reveal information about in
vivo MMP-1 activity and the ratio of MMP-1/TIMPs. Further-
more, the relative amounts of active and latent MMP-1 could
be determined, because both forms are recognized with the
antibody used in this study.
The saccular stage of fetal lung development is characterized
by alveoli mainly lined by type-II pneumocytes. During this
stage, thinning of the interstitial matrix between alveoli occurs.
Table 2. Localization of MMP-1, TIMP-1, and TIMP-2 during different phases of BPD and in control tissue
Acute phase Regenerative phase Transitional phase Chronic phase Control tissue
MMP-1 TIMP-1 TIMP-2 MMP-1 TIMP-1 TIMP-2 MMP-1 TIMP-1 TIMP-2 MMP-1 TIMP-1 TIMP-2 MMP-1 TIMP-1 TIMP-2
Type-II pneumocytes               
Alveolar basement
membrane
              
Alveolar macrophages               
Fibroblasts in fibrotic
area
              
  immunoreactivity.
  no immunoreactivity.
Figure 1. Immunohistochemical staining of control lung tissue. MMP-1 (A),
TIMP-1 (B), and TIMP-2 (C) immunoreactivity is detected in type-II pneu-
mocytes (arrow) and alveolar macrophages. TIMP-1 (B) immunoreactivity is
detected in the alveolar basement membrane (arrowhead).
Figure 2. Immunohistochemical staining of lung tissue in the regenerative
phase of BPD development. MMP-1 (A), TIMP-1 (B), and TIMP-2 (C)
immunoreactivity is detected in type-II pneumocytes re-epithelializing the
alveoli and incorporating hyaline membranes (arrow).
Figure 3. Immunohistochemical staining of lung tissue in the transitional
phase of BPD development. MMP-1 (A), TIMP-1 (B), and TIMP-2 (C)
immunoreactivity is detected in type-II pneumocytes covering the entire
alveolar surface (arrow) and in alveolar macrophages.
Figure 4. Immunohistochemical staining of lung tissue in the chronic phase
of BPD development. MMP-1 (A), TIMP-1 (B), and TIMP-2 (C) immunore-
activity is detected in fibroblasts present in fibrotic foci (arrow) and in type-II
pneumocytes covering the entire alveolar surface. 4D is negative control.
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It has been suggested that epithelial cells over-expressing
MMP-1 relative to TIMP-1 contribute to the net degradation of
interstitial collagens during this process (36–39). During the
transitional and chronic phase of BPD we observed virtually no
hyaline membranes and the alveoli were almost exclusively
lined by hyperplastic MMP-1, TIMP-1, and -2 positive type-II
pneumocytes. Furthermore, fibrotic areas in the alveolar septa
were clearly present in chronic BPD. Fibrotic areas are char-
acterized by increased numbers of fibroblasts and accumulation
of fibrillar collagens, mainly collagens type-I and type-III (3,
40–43). MMP-1 exerts collagenolytic activity against fibrillar
collagen. We observed increased staining intensity for TIMP-1
in type-II pneumocytes in the chronic phase of BPD compared
with the earlier phases, whereas no difference in MMP-1
staining intensity in type-II pneumocytes was observed. This
might result in an increased TIMP-1/MMP-1 ratio leading to
decreased collagenolytic activity by type-II pneumocytes,
thereby favoring interstitial collagen accumulation (fibrosis) as
is observed in chronic BPD and is opposed to normal lung
development.
Fibroblasts are the key cells in a fibrotic response, contrib-
uting to collagen deposition via increased proliferation, in-
creased collagen synthesis, or decreased collagen breakdown
(44). Lung tissue from patients with idiopathic pulmonary
fibrosis has been shown to contain decreased collagenolytic
activity and lung fibroblasts from these patients show an
increased ratio of TIMP/MMP-1 compared with normal lung
fibroblasts (25, 45). It has been suggested that co-expression of
MMP-1 and TIMP-2 in fibroblasts in fibrotic foci from patients
with idiopathic pulmonary fibrosis contributes to progressive
collagen deposition caused by decreased collagenolytic activ-
ity. On the other hand, a predominance of MMP-1 in fibro-
blasts in fibrotic foci in bronchiolitis obliterans organizing
pneumonia could explain the reversibility of fibrotic changes in
that disease (27). Our study revealed that during the chronic
phase of BPD, fibroblasts in fibrotic areas were associated with
the expression of MMP-1, TIMP-1, and TIMP-2. Inhibition of
collagen degradation by decreasing the production of MMP-1
and increasing the production of TIMPs by fibroblasts has been
reported for transforming growth factor- (TGF-1) (46).
Interestingly, intense immunoreactivity for TGF-1 has been
shown in alveolar macrophages and fibroblasts in lung tissue
during the regenerative and transitional stages of BPD (37).
Therefore, during BPD development TGF-1 could increase
the TIMP/MMP-1 ratio in fibroblasts. This would lead to a
decreased collagenolytic activity and favors net deposition of
collagen by fibroblasts, thereby contributing to fibrosis of the
lung tissue.
In the present study we observed MMP-1 expression in
type-II epithelial cells re-epithelializing the injured alveoli.
From the literature there is abundant evidence that MMP-1 is
involved in re-epithelialization after injury. Therefore, this may
suggest a role for MMP-1 expressed by type-II pneumocytes in
the re-epithelialization process after acute injury during the
acute and regenerative phase of BPD development. The in-
crease in intensity of TIMP-1 relative to MMP-1 in type-II
pneumocytes during the chronic phase of BPD might result in
decreased interstitial collagen breakdown, thereby contributing
to fibrosis as observed in chronic BPD. Furthermore, fibro-
blasts co-expressing MMP-1 and TIMPs in fibrotic areas may
contribute to fibrosis in chronic BPD via a decreased collag-
enolytic activity, due to an increased TIMP/MMP-1 ratio.
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